ReShape Dual Balloon Enters U.S. Market, Headlining Week Of Obesity Device News
This article was originally published in The Pink Sheet Daily
It was a banner day for minimally invasive weight-loss devices July 28. FDA approved ReShape Medical's intragastric balloon and Aspire Bariatrics submitted an application for its AspireAssist aspiration therapy system for obesity. Two days later, GI Dynamics announced the termination of a pivotal study for its Endobarrier device.
You may also be interested in...
FDA and the company could not come up with a plan to continue the ENDO study for GI's device targeting obese patients with diabetes in response to higher-than-anticipated rates of liver infection. The company suggests, however, that development of the device will continue.
Several emerging medtechs are developing products and procedures that are less invasive, less expensive, easier to deliver, and more easily reversible than bariatric surgery. With support from investors and the FDA, these firms are poised to reap big rewards in the massive, undermet obesity market.
Nearly half of the world’s adult population will be overweight or obese by 2030 and obesity is tied to more than 40 diseases. Enterprising companies are heeding the call with increasingly less invasive weight loss devices, while an amenable regulatory environment means the marketplace will welcome some of these innovations in 2015.